Trade Quince Therapeuticks Inc - QNCX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0462 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.0469 |
| Open | 1.0269 |
| 1-Year Change | -33.69% |
| Day's Range | 1.0169 - 1.0569 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2024 | 1.0469 | 0.0000 | 0.00% | 1.0469 | 1.0869 | 1.0269 |
| Apr 23, 2024 | 1.0769 | 0.0400 | 3.86% | 1.0369 | 1.0969 | 1.0269 |
| Apr 22, 2024 | 1.0469 | 0.0200 | 1.95% | 1.0269 | 1.0669 | 1.0069 |
| Apr 19, 2024 | 1.0269 | 0.0000 | 0.00% | 1.0269 | 1.0569 | 1.0069 |
| Apr 18, 2024 | 1.0269 | 0.0200 | 1.99% | 1.0069 | 1.0369 | 0.9967 |
| Apr 17, 2024 | 0.9742 | 0.0211 | 2.21% | 0.9531 | 0.9967 | 0.9531 |
| Apr 16, 2024 | 0.9641 | -0.0328 | -3.29% | 0.9969 | 0.9969 | 0.9354 |
| Apr 15, 2024 | 0.9838 | 0.0169 | 1.75% | 0.9669 | 0.9969 | 0.9631 |
| Apr 12, 2024 | 0.9273 | -0.0258 | -2.71% | 0.9531 | 0.9531 | 0.8834 |
| Apr 11, 2024 | 0.9843 | 0.0212 | 2.20% | 0.9631 | 0.9923 | 0.9473 |
| Apr 10, 2024 | 0.9717 | -0.0352 | -3.50% | 1.0069 | 1.0169 | 0.9716 |
| Apr 9, 2024 | 1.0669 | 0.0300 | 2.89% | 1.0369 | 1.0669 | 1.0169 |
| Apr 8, 2024 | 0.9969 | 0.0002 | 0.02% | 0.9967 | 1.0269 | 0.9967 |
| Apr 5, 2024 | 0.9969 | -0.0100 | -0.99% | 1.0069 | 1.0169 | 0.9969 |
| Apr 4, 2024 | 1.0169 | 0.0000 | 0.00% | 1.0169 | 1.0269 | 0.9967 |
| Apr 3, 2024 | 1.0069 | -0.0300 | -2.89% | 1.0369 | 1.0369 | 0.9967 |
| Apr 2, 2024 | 1.0169 | -0.0300 | -2.87% | 1.0469 | 1.0469 | 1.0069 |
| Apr 1, 2024 | 1.0769 | 0.0500 | 4.87% | 1.0269 | 1.0969 | 1.0269 |
| Mar 28, 2024 | 1.0469 | -0.0600 | -5.42% | 1.1069 | 1.1069 | 1.0269 |
| Mar 27, 2024 | 1.0869 | -0.0600 | -5.23% | 1.1469 | 1.1469 | 1.0369 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Cortexyme Inc. Company profile
About Cortexyme Inc
Cortexyme, Inc. is a clinical stage biopharmaceutical company that is focused on providing disease-modifying therapeutics to treat Alzheimer's and other degenerative diseases. The Company provides 3CLpro inhibitor, COR803 product, is a lead compound for treatment of coronavirus infections. The Company’s products pipeline includes drug candidates for the treatment of central nervous system (CNS) disorders including Alzheimer’s disease; for the treatment of oncology applications including the prevention of oral squamous cell carcinoma, and for the treatment of underserved and chronic conditions such as periodontitis. The Company’s COR388 is for the treatment of Alzheimer’s disease and Parkinson's disease. The Company's COR588 is in Phase I clinical trial and targeting to use in the treatment of periodontal disease and other P. gingivalis-related indications. The Company is also developing COR588, is a second-generation brain penetrant lysine gingipain inhibitor.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cortexyme Inc revenues was not reported. Net loss increased 17% to $89.9M. Higher net loss reflects Stock-based Compensation in R&D increase from $7M to $15.1M (expense), Stock-based Compensation in GA increase of 99% to $14.8M (expense), General and administrative - Balancing increase of 45% to $14.7M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
601 Gateway Boulevard, Suite 1250
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com